Targeting tumor microvessels using doxorubicin encapsulated in a novel thermosensitive liposome
- PMID: 15486198
Targeting tumor microvessels using doxorubicin encapsulated in a novel thermosensitive liposome
Abstract
Liposomal drugs accumulate only in perivascular regions in tumors after i.v. injection. Thus, they cannot kill tumor cells in deeper tissue layers. To circumvent this problem, we investigated effects of doxorubicin (DOX) encapsulated in a lysolecithin-containing thermosensitive liposome (LTSL) on tumor microcirculation because damaging microvessels would stop nutrient supply to deeper tumor cells. We used LTSL-DOX in combination with hyperthermia to treat a human squamous carcinoma xenograft (FaDu) implanted in dorsal skinfold chambers in nude mice. Before the treatment, the RBC velocity in tumors was 0.428 +/- 0.037 mm/s and the microvascular density was 3.93 +/- 0.44 mm/mm(2). At 24 hours after the treatment, they were reduced to 0.003 +/- 0.003 mm/s and 0.86 +/- 0.27 mm/mm(2), respectively. The same treatment, however, caused only 32% decrease in the RBC velocity and no apparent change in microvascular networks in normal s.c. tissues over the same period. LTSL and LTSL-DOX alone had no effect on tumor microcirculation, and LTSL plus hyperthermia caused only a transient decrease in the RBC velocity in tumors. At 24 hours after treatments, tumor microcirculation in all these control experiments was insignificantly different from that before the treatments. We also examined apoptosis of cells in tumors at different time points after LTSL-DOX plus hyperthermia treatment and observed few apoptotic cells in tumor microvessels. In conclusion, the rapid release of DOX during hyperthermia could make the drug to shutdown tumor blood flow while have only minor effects on normal microcirculation in s.c. tissues.
Similar articles
-
Tumor microvascular permeability is a key determinant for antivascular effects of doxorubicin encapsulated in a temperature sensitive liposome.Int J Hyperthermia. 2008 Sep;24(6):475-82. doi: 10.1080/02656730701854767. Int J Hyperthermia. 2008. PMID: 18608573 Free PMC article.
-
Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release.Cancer Res. 2000 Dec 15;60(24):6950-7. Cancer Res. 2000. PMID: 11156395
-
The antitumor activity of tumor-homing peptide-modified thermosensitive liposomes containing doxorubicin on MCF-7/ADR: in vitro and in vivo.Int J Nanomedicine. 2015 Mar 19;10:2229-48. doi: 10.2147/IJN.S79840. eCollection 2015. Int J Nanomedicine. 2015. PMID: 25834435 Free PMC article.
-
Comparative effects of thermosensitive doxorubicin-containing liposomes and hyperthermia in human and murine tumours.Int J Hyperthermia. 2010;26(5):485-98. doi: 10.3109/02656731003789284. Int J Hyperthermia. 2010. PMID: 20597627 Free PMC article.
-
Mild hyperthermia triggered doxorubicin release from optimized stealth thermosensitive liposomes improves intratumoral drug delivery and efficacy.J Control Release. 2013 Jun 10;168(2):142-50. doi: 10.1016/j.jconrel.2013.03.011. Epub 2013 Mar 21. J Control Release. 2013. PMID: 23524188
Cited by
-
Non-invasive monitoring of intra-tumor drug concentration and therapeutic response using optical spectroscopy.J Control Release. 2010 Mar 19;142(3):457-64. doi: 10.1016/j.jconrel.2009.10.034. Epub 2009 Nov 5. J Control Release. 2010. PMID: 19896999 Free PMC article.
-
Rationale for and measurement of liposomal drug delivery with hyperthermia using non-invasive imaging techniques.Int J Hyperthermia. 2008 Feb;24(1):79-90. doi: 10.1080/02656730701840147. Int J Hyperthermia. 2008. PMID: 18214771 Free PMC article. Review.
-
Mouse tumor vasculature expresses NKG2D ligands and can be targeted by chimeric NKG2D-modified T cells.J Immunol. 2013 Mar 1;190(5):2455-63. doi: 10.4049/jimmunol.1201314. Epub 2013 Jan 25. J Immunol. 2013. PMID: 23355740 Free PMC article.
-
Thermo-Sensitive Liposome co-Loaded of Vincristine and Doxorubicin Based on Their Similar Physicochemical Properties had Synergism on Tumor Treatment.Pharm Res. 2016 Aug;33(8):1881-98. doi: 10.1007/s11095-016-1924-2. Epub 2016 Apr 13. Pharm Res. 2016. PMID: 27075873
-
Mechanisms of tumor vascular priming by a nanoparticulate doxorubicin formulation.Pharm Res. 2012 Dec;29(12):3312-24. doi: 10.1007/s11095-012-0823-4. Epub 2012 Jul 14. Pharm Res. 2012. PMID: 22798260 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources